Medline Inc.(MDLN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MDLN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Medline Inc. (MDLN), a Healthcare sector company. MDLN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Medline Inc. reports quarterly revenue of $7.4B, net income of $239.0M, an operating margin of 5.7%. Top institutional holders of MDLN by reported 13-F value include Carlyle Group, H&F Corporate Investors X, Ltd., FMR, based on the most recent SEC filings. MDLN trades on the Nasdaq exchange and files with the SEC under CIK 2046386. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medline Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$7.4B
Net Income
Q1 2026
$239.0M
Free Cash Flow
Q1 2026
$316.0M
Operating Margin
Q1 2026
5.7%
ROIC
Q1 2026
1.8%
D/E Ratio
Q1 2026
1.12
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+9.8% YoYOperating Income
+71.7% YoYTotal Assets
Total Debt
Op. Cash Flow
+5.0% YoY| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Revenue | $25.51B +9.8% | $23.23B |
| Operating Income | $2.15B +71.7% | $1.25B |
| Total Assets | $35.98B | — |
| Total Debt | $16.57B | — |
| Operating Cash Flow | $1.77B +5.0% | $1.69B |
AI Insight: MDLN Financial Trends
Only one quarter of P&L data available — Medline posts $422M operating income on $7,352M revenue in Q1 2026, but trend analysis requires more periods.
• Q1 2026 operating margin stands at 5.7% ($422M op income on $7,352M revenue), with net margin at 4.3%.
• Operating cash flow of $412M in Q1 2026 closely tracks operating income, suggesting high earnings quality.
• Equity grew from $10,737M in Q4 2025 to $11,272M in Q1 2026, a $535M increase in one quarter.
⚠ Total debt is $12,649M against $11,272M equity — debt-to-equity above 1.1x warrants ongoing leverage monitoring.
⚠ Only one income-statement period available; margin and cash flow trends cannot yet be established.
AI Insight: MDLN Ratio Trends
Only one quarter of profitability data available — meaningful trend analysis requires additional periods.
• Q1 2026 operating margin stands at 5.7% and net profit margin at 4.3%, but no prior-period comparison exists.
• D/E ratio edged down from 1.18 in Q4 2025 to 1.12 in Q1 2026, suggesting modest deleveraging.
⚠ With only one quarter of margin data, it is impossible to confirm whether 5.7% operating margin is improving or deteriorating.
⚠ ROIC of 7.1% and ROE of 11.3% in Q1 2026 need subsequent quarters to assess trajectory against leverage levels.
Get alerted when MDLN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Medline Inc. including:
Top Institutional Holders of MDLN
Carlyle Group Inc.
$8.3B187,083,713 shH&F Corporate Investors X, Ltd.
$3.8B86,473,497 shFMR LLC
$1.6B36,556,201 shCapital Research Global Investors
$1.0B23,161,670 shInvesco Ltd.
$932.9M20,963,615 shBlackRock, Inc.
$753.1M16,923,660 shMORGAN STANLEY
$698.8M15,702,903 shVANGUARD CAPITAL MANAGEMENT LLC
$655.5M14,729,681 shVANGUARD PORTFOLIO MANAGEMENT LLC
$629.7M14,150,752 shLONE PINE CAPITAL LLC
$524.6M11,789,156 sh
| Fund | Value | Shares |
|---|---|---|
| Carlyle Group Inc. | $8.3B | 187,083,713 |
| H&F Corporate Investors X, Ltd. | $3.8B | 86,473,497 |
| FMR LLC | $1.6B | 36,556,201 |
| Capital Research Global Investors | $1.0B | 23,161,670 |
| Invesco Ltd. | $932.9M | 20,963,615 |
| BlackRock, Inc. | $753.1M | 16,923,660 |
| MORGAN STANLEY | $698.8M | 15,702,903 |
| VANGUARD CAPITAL MANAGEMENT LLC | $655.5M | 14,729,681 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $629.7M | 14,150,752 |
| LONE PINE CAPITAL LLC | $524.6M | 11,789,156 |
More Healthcare Companies
View all Healthcare →Put MDLN on your watchlist
Track score changes the day Medline Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MDLN a good stock to buy?
13F Pro's AI-powered analysis of Medline Inc. (MDLN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDLN are available on the MDLN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MDLN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDLN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medline Inc.'s investment landscape.